We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

First-Ever Saliva-Based Concussion Test to Be Available in 2023

By LabMedica International staff writers
Posted on 21 Nov 2022
Print article
Image: The Clarifi mTBI saliva test collection device (Photo courtesy of Quadrant Biosciences)
Image: The Clarifi mTBI saliva test collection device (Photo courtesy of Quadrant Biosciences)

According to the (CDC), 1.6 to 3.8 million athletes will experience a sports-related mild traumatic brain injury (mTBI) or concussion each year. Despite increased public awareness, clinical guidelines still rely on subjective symptom scales to diagnose and manage concussions. Furthermore, there are currently no biological tests to diagnose mTBI. Now, new research has revealed that biomarkers found in saliva may distinguish mTBI and parallel symptom recovery.

By analyzing brain derived biomarkers found in saliva, scientists at Quadrant Biosciences (Syracuse, NY, USA), in collaboration with Penn State (Hershey, PA, USA) and the State University of New York (New York, NY, USA), have developed a novel diagnostic test for concussion. These biomarkers can confirm mTBI when run through Quadrant’s proprietary artificial intelligence platform. The Clarifi mTBI Saliva Test being developed by Quadrant uses small non-coding RNAs found in the saliva to help diagnose concussions. The U.S. Patent and Trademark Office (USPTO) has awarded the company and its academic partners with a patent for the analysis and prediction of mTBI and concussion symptoms. Quadrant has started discussions about potentially licensing this technology to third-parties, and the test is expected to be available in late 2023.

"Our motivation for developing this technology was to prevent further harm to the kids, athletes, and adults who experience mild, moderate, or repetitive head impacts," said Dr. Frank Middleton, PhD, Professor at SUNY Upstate Medical University, who led the patented research. "While most of the field has focused on peripheral blood measures, for the past decade we worked extensively to establish the utility of quantifying small RNA molecules in saliva as predictors of concussion or long-lasting symptoms from head impacts."

"As a pediatrician who provides medical care for children and teens with concussion, I am excited by the potential of this technology to improve the way clinicians manage this common injury. A saliva-based test for concussion could provide a novel addition to the physician toolbox," said Dr. Steve Hicks, MD, PhD, at Penn State College of Medicine, who was also among the ones to lead the patented research.

Related Links:
Penn State
Quadrant Biosciences
State University of New York 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.